Ritholtz Wealth Management Boosts Gilead Sciences Stake

Institutional investor adds over 7,800 shares of biotech giant in Q4

Apr. 11, 2026 at 11:06am

Got story updates? Submit your updates here. ›

An extreme close-up of highly detailed, interlocking metal gears and machinery, representing the complex financial infrastructure and institutional power of the pharmaceutical industry.Ritholtz Wealth Management's increased investment in Gilead Sciences reflects the firm's confidence in the pharmaceutical company's financial strength and growth potential.Foster City Today

Ritholtz Wealth Management, a prominent investment management firm, increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.2% during the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 135,318 shares of the biopharmaceutical company's stock, valued at over $16.6 million.

Why it matters

Gilead Sciences is a major player in the biotech industry, known for its antiviral therapies and expanding into oncology, cell therapy, and inflammatory diseases. Institutional investors' moves in and out of the stock can signal broader market trends and investor sentiment around the company's performance and future prospects.

The details

Ritholtz Wealth Management added 7,865 shares of Gilead Sciences during the fourth quarter, bringing its total position to 135,318 shares. The firm's holdings in the company are now valued at $16.6 million, up from $15.6 million in the previous quarter. This move reflects Ritholtz's confidence in Gilead's long-term growth potential and the firm's belief that the stock is undervalued.

  • Ritholtz Wealth Management filed its latest 13F report with the SEC on April 11, 2026, disclosing its Q4 2025 holdings.
  • The firm increased its Gilead Sciences position during the fourth quarter of 2025.

The players

Ritholtz Wealth Management

A prominent investment management firm that manages over $5 billion in assets for individual and institutional clients.

Gilead Sciences, Inc.

A leading biopharmaceutical company focused on developing and commercializing innovative medicines in areas of high unmet medical need, including HIV, viral hepatitis, oncology, and inflammatory diseases.

Got photos? Submit your photos here. ›

What they’re saying

“Gilead Sciences is a core holding in our portfolio, and we continue to see significant upside potential in the stock.”

— Barry Ritholtz, Founder and Chief Investment Officer, Ritholtz Wealth Management

What’s next

Investors will be closely watching Gilead Sciences' upcoming earnings report and any updates on the company's pipeline and strategic initiatives. The stock's performance will also be influenced by broader market conditions and investor sentiment in the biotech sector.

The takeaway

Ritholtz Wealth Management's increased stake in Gilead Sciences reflects the firm's confidence in the company's long-term growth prospects. As a major institutional investor, Ritholtz's move could signal broader market optimism around Gilead's ability to navigate the evolving biotech landscape and deliver value for shareholders.